ES2893126T8 - Métodos de tratamiento de afecciones oculares - Google Patents

Métodos de tratamiento de afecciones oculares

Info

Publication number
ES2893126T8
ES2893126T8 ES17718304T ES17718304T ES2893126T8 ES 2893126 T8 ES2893126 T8 ES 2893126T8 ES 17718304 T ES17718304 T ES 17718304T ES 17718304 T ES17718304 T ES 17718304T ES 2893126 T8 ES2893126 T8 ES 2893126T8
Authority
ES
Spain
Prior art keywords
treatment methods
eye conditions
eye
conditions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17718304T
Other languages
English (en)
Other versions
ES2893126T3 (es
Inventor
Douglas Michael Ackermann
James Loudin
Kenneth J Mandell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oyster Point Pharma Inc
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Application granted granted Critical
Publication of ES2893126T3 publication Critical patent/ES2893126T3/es
Publication of ES2893126T8 publication Critical patent/ES2893126T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES17718304T 2016-04-07 2017-04-06 Métodos de tratamiento de afecciones oculares Active ES2893126T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
ES2893126T3 ES2893126T3 (es) 2022-02-08
ES2893126T8 true ES2893126T8 (es) 2022-05-23

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17718304T Active ES2893126T3 (es) 2016-04-07 2017-04-06 Métodos de tratamiento de afecciones oculares

Country Status (21)

Country Link
US (2) US10709707B2 (es)
EP (2) EP3439661B1 (es)
JP (3) JP7090551B2 (es)
KR (2) KR102485299B1 (es)
CN (3) CN114432313A (es)
AU (1) AU2017248276B2 (es)
BR (1) BR112018070497A2 (es)
CA (1) CA3020170A1 (es)
DK (1) DK3439661T3 (es)
EA (1) EA201892265A1 (es)
ES (1) ES2893126T3 (es)
IL (3) IL299204A (es)
MX (2) MX2018012230A (es)
MY (1) MY199237A (es)
NZ (2) NZ785093A (es)
PH (1) PH12018502154A1 (es)
PT (1) PT3439661T (es)
SG (1) SG11201808650QA (es)
TW (2) TWI790997B (es)
WO (1) WO2017177024A1 (es)
ZA (1) ZA201807438B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
ES2848977T5 (es) 2014-10-20 2024-06-06 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
KR102485299B1 (ko) * 2016-04-07 2023-01-06 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
EP4333855A1 (en) * 2021-05-07 2024-03-13 Oyster Point Pharma, Inc. Co-therapy with vector and nicotinic agonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
AU2002341327A1 (en) 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
BRPI0515932A (pt) 2004-10-15 2008-08-12 Pfizer Prod Inc composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina
WO2006100075A2 (en) 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
MY153057A (en) 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
KR20100122508A (ko) 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
JP2012502039A (ja) 2008-09-05 2012-01-26 ターガセプト，インコーポレイテッド ジアザビシクロオクタンのアミド及びその用途
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010045212A2 (en) * 2008-10-14 2010-04-22 Psychogenics, Incstatuts Nicotinic acetylcholine receptor ligands and the uses thereof
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
IL266097B (en) 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
MX2011013860A (es) * 2009-06-17 2012-01-30 Targacept Inc Inversion de la discinesia inducida por levopoda mediante los ligandos del receptor nicotinico neural.
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
EP2768507B1 (en) 2011-10-20 2019-12-11 Novartis AG Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
EP3029463A1 (en) 2011-11-30 2016-06-08 DiagnosTear Ltd Dry eye diagnostic
ES2848977T5 (es) 2014-10-20 2024-06-06 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
KR102485299B1 (ko) * 2016-04-07 2023-01-06 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법

Also Published As

Publication number Publication date
WO2017177024A8 (en) 2018-11-08
JP2024103594A (ja) 2024-08-01
WO2017177024A1 (en) 2017-10-12
CN114533737A (zh) 2022-05-27
JP2019513759A (ja) 2019-05-30
NZ785093A (en) 2024-07-05
MX2021010399A (es) 2022-01-18
EP3439661A1 (en) 2019-02-13
TWI790997B (zh) 2023-02-01
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
CN109310692B (zh) 2022-01-25
IL290069B2 (en) 2023-05-01
CN109310692A (zh) 2019-02-05
MX2018012230A (es) 2019-03-28
IL290069B1 (en) 2023-01-01
TW201737917A (zh) 2017-11-01
CN114533737B (zh) 2024-05-31
EP3970724A1 (en) 2022-03-23
CN114432313A (zh) 2022-05-06
NZ746468A (en) 2023-06-30
EP3439661B1 (en) 2021-08-04
KR20230010813A (ko) 2023-01-19
SG11201808650QA (en) 2018-10-30
JP7090551B2 (ja) 2022-06-24
CA3020170A1 (en) 2017-10-12
US20190201397A1 (en) 2019-07-04
KR102485299B1 (ko) 2023-01-06
PT3439661T (pt) 2021-09-30
DK3439661T3 (da) 2021-10-18
TW202320785A (zh) 2023-06-01
ES2893126T3 (es) 2022-02-08
JP2022120125A (ja) 2022-08-17
AU2017248276A1 (en) 2018-11-22
MY199237A (en) 2023-10-22
IL290069A (en) 2022-03-01
US20200345734A1 (en) 2020-11-05
KR102512777B1 (ko) 2023-03-23
EA201892265A1 (ru) 2019-04-30
IL262102A (en) 2018-11-29
IL262102B (en) 2022-03-01
IL299204A (en) 2023-02-01
AU2017248276B2 (en) 2023-07-13
KR20190005859A (ko) 2019-01-16
BR112018070497A2 (pt) 2019-01-29
ZA201807438B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
DK3389778T3 (da) Indretning til fotodynamisk behandling
BR112016027906A2 (pt) operação à prova de falhas de dispositivo montável no olho
BR112016016792A2 (pt) Aparelho para tratamento de vestuário
DK3393579T3 (da) Øjenbehandlingssystem
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3231444T3 (da) Ny behandling
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DE112017002419A5 (de) Augenchirurgisches Verfahren
DK3273947T3 (da) Sammensætning for øjensundhed
BR112018000204A2 (pt) métodos de tratamento de colite
IL251769A0 (en) Methods for treating eye conditions
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
ES2981980T3 (es) Dispositivo implantable de crecimiento autónomo
ES2982192T3 (es) Dispositivo de neuromodulación
DK3250168T3 (da) Forbedringer vedrørende nethindebehandling
DK3903774T3 (da) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
ES1167558Y (es) Dispositivo optométrico funcional
ITUB20156017A1 (it) Collirio oftalmico
HUP1500621A2 (en) Low-powered light-therapy device for eye treatment
UA31684S (uk) Пристосування для обробки води
FI20150082A (fi) Hoitoväline